1. Hollnberger J, Liu Y, Xu S, Chang S, Martin R, Manhas S, Aeschbacher T, Han B, Yazdi T, May L, Han D, Shornikov A, Flaherty J, Manuilov D, Suri V, Asselah T, Lampertico P, Wedemeyer H, Aleman S, Richards C, Mateo R, Maiorova E, Cihlar T, Mo H, Urban S. (2023) No virologic resistance to bulevirtide monotherapy detected in patients through 24 weeks treatment in phase II and III clinical trials for chronic hepatitis delta. J. Hepatol. doi: 10.1016/j.jhep.2023.04.0272. Wedemeyer H, Schöneweis K, Bogomolov P, Blank A, Voronkova N, Stepanova T, Sagalova O, Chulanov V, Osipenko M, Morozov V, Geyvandova N, Sleptsova S, Bakulin I, Khaertynova I, Rusanova M, Pathil A, Merle U, Bremer B, Allweiss L, Lempp F, Port K, Haag M, Schwab M, Schulze zur Wiesch J, Cornberg M, Haefeli W, Dandri M, Alexandrov A, Urban S. (2023) Safety and efficacy of bulevirtide in combination with tenofovir disoproxil fumarate in patients with hepatitis B virus and hepatitis D virus coinfection (MYR202): a multicentre, randomised, parallel-group, open-label, phase 2 trial. Lancet Infect Dis 23(1):117-129. doi:10.1016/S1473-3099(22)00318-83. Bogomolov P, Alexandrov A, Voronkova N, Macievich M, Kokina K, Petrachenkova M, Lehr T, Lempp FA, Wedemeyer H, Haag M, Schwab M, Haefeli WE, Blank A, Urban S. (2016) Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: First results of a phase Ib/IIa study. J. Hepatol 65(3):490-8. doi: 10.1016/j.jhep.2016.04.0163. Hoh A, Heeg M, Ni Y, Schuch A, Binder B, Hennecke N, Blum HE, Nassal M, Protzer U, Hofmann M, Urban S, Thimme R. HBV-infected HepG2hNTCP cells serve as a novel immunological tool to analyze the antiviral efficacy of CD8+ T cells in vitro. J Virol. 2015. May 13. pii: JVI.00605-15. doi: 10.1128/JVI.00605-154. Ni Y, Lempp FA, Mehrle S, Nkongolo S, Kaufman C, Fälth M, Stindt J, Königer C, Nassal M, Kubitz R and Urban S. (2014) Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes. Gastroenterology 14;146:1070-1083. doi: 10.1053/j.gastro.2013.12.0245. Urban S, Bartenschlager R, Kubitz R, Zoulim F. (2014) Strategies to inhibit entry of HBV and HDV into hepatocytes. Gastroenterology 14;7:48-64. doi: 10.1053/j.gastro.2014.04.0306. Petersen J, Dandri M, Mier W, Lutgehetmann M, Volz T, von WF, Haberkorn U, Fischer L, Pollok JM, Erbes B, Seitz S, Urban S. (2008) Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein. Nat Biotechnol. 26:335-341. doi: 10.1038/nbt13897. Seitz S*, Urban S*, Antoni C and Böttcher B. (2007) Cryo-electron microscopy of hepatitis B virions reveals variability in envelope capsid interactions. EMBO J. 26:4160-4167. doi: 10.1038/sj.emboj.7601841 * equal contribution8. Gripon P, Cannie I, Urban S. 2005 Efficient inhibition of hepatitis B virus infection by acylated peptides derived from the large viral surface protein. J. Virol. 79(3):1613-22. doi: 10.1128/JVI.79.3.1613-1622.20059. Gripon P, Rumin S, Urban S, Le Seyec J, Glaise D, Cannie I, Guyomard C, Lucas J, Trepo C, Guguen-Guillouzo C. (2002) Infection of a human hepatoma cell line by hepatitis B virus. Proc Natl Acad Sci U S A., 99(24):15655-15660. doi: 10.1073/pnas.232137699